Idogen sharpens focus on its IDO 8 program and lowers operating expenditure
The Board of Directors of Idogen AB (publ) announced today its decision to focus all development activities on its IDO 8 program. Idogen will shortly commence the Phase I/IIa clinical trial of its drug candidate in the IDO 8 program for patients who suffer from hemophilia and have developed antibodies against their vital factor VIII treatment. This is the company’s most important milestone to date. The decision to pause the IDO T and IDO AID programs temporarily in combination with other efficiency enhancement measures, will allow the company to drastically lower its operating expenditure.